OncoMatch/Clinical Trials/NCT06745882
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Is NCT06745882 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for non-small cell lung cancer.
Treatment: Cisplatin · Carboplatin · Pemetrexed · Pembrolizumab · Abraxane · Paclitaxel — This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age, ECOG performance status 0-2, and may have detectable ctDNA at baseline.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Required: EGFR wild-type
Required: ROS1 wild-type
Disease stage
Metastatic disease required
advanced/metastatic NSCLC
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Exception: adjuvant/neoadjuvant/definitive chemoradiation and/or immunotherapy for locally advanced disease completed ≥ 6 months before recurrence is allowed
Be treatment naïve in the advanced/metastatic/recurrent disease setting. Patients who received platinum-containing adjuvant chemotherapy, neoadjuvant chemotherapy or definitive chemoradiation and/or neoadjuvant and/or adjuvant immunotherapy and/or consolidation immunotherapy therapy given for locally advanced disease and developed recurrent (local or metastatic) disease ≥ 6 months of completing therapy are eligible.
Cannot have received: immune checkpoint inhibitor
Exception: adjuvant/neoadjuvant/consolidation immunotherapy for locally advanced disease completed ≥ 6 months before recurrence is allowed
Be treatment naïve in the advanced/metastatic/recurrent disease setting. Patients who received ... immunotherapy ... for locally advanced disease and developed recurrent (local or metastatic) disease ≥ 6 months of completing therapy are eligible.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Moffitt Cancer Center · Tampa, Florida
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center · Baltimore, Maryland
- TidalHealth Peninsula Regional · Salisbury, Maryland
- Baptist Clinical Research Institute · Memphis, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify